Evidence map›Paper›PMID 41444397›Full record

ReviewInternational journal of obesity (2005)2026

Postbiotics: emerging regulatory mechanisms and therapeutic applications in obesity and its complications.

Guoliang Zhou, Rongzhi Wang, Chengxiao Fu, Yue Du, Xiang Li, Qing Xia, JiaRu Zhou, Zixi Li, Xiangzhen Li, Chengxin Gong and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guoliang Zhou *Department of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Rongzhi Wang *Joint program of Nanchang University and Queen Mary University of London, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Chengxiao FuDepartment of Medical Imaging, Jiangxi Armed Police Corps Hospital, Nanchang, China.
Yue DuDepartment of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xiang LiJoint program of Nanchang University and Queen Mary University of London, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Qing XiaDepartment of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
JiaRu ZhouJoint program of Nanchang University and Queen Mary University of London, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Zixi LiJoint program of Nanchang University and Queen Mary University of London, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xiangzhen LiJoint program of Nanchang University and Queen Mary University of London, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Chengxin GongDepartment of Science and Education, The Third Affiliated Hospital of Nanchang Medical College, Jiangxi Chest Hospital, Nanchang, Jiangxi, China.
Yuting SunDepartment of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Hong XuDepartment of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. hxu@ncu.edu.cn.ORCID 0000-0001-6907-2473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a growing global health issue, leading to complications such as cardiovascular diseases, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and chronic inflammation. Existing treatments for people with obesity, including lifestyle changes, pharmaceutical interventions, and surgical procedures, have certain limitations, highlighting the need for alternative therapies. Postbiotics, as inanimate microbial metabolites, offer a novel therapeutic approach. This review discusses how postbiotics exert anti-obesity effects through various mechanisms, including regulation of lipid metabolism and energy homeostasis, gut microbiota modulation, endogenous systemic regulation, inflammatory immunomodulation and intestinal barrier function enhancement, along with other synergistic effects. Our work also evaluates their clinical application potential, emphasizing the safety, efficacy, and advantages over traditional treatments like pharmaceuticals and surgery. Despite promising early clinical trial results, challenges remain in translating postbiotics into clinical practice, including the need for long-term studies to assess their sustained efficacy and safety, standardized production processes, scalability, and addressing individual variability in treatment responses. Overall, postbiotics represent a sustainable and personalized therapeutic strategy for managing obesity and its complications.

Indexed as

Gastrointestinal MicrobiomeObesityDiabetes Mellitus, Type 2HumansLipid MetabolismNon-alcoholic Fatty Liver Disease

Identifiers

PMID41444397

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.